Neurocrine Biosciences, Inc. (BIT:1NBIX)
Italy flag Italy · Delayed Price · Currency is EUR
110.90
-1.90 (-1.68%)
At close: Mar 6, 2026

Neurocrine Biosciences Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
713233251.1262.9340.8
Short-Term Investments
767.4843.1780.5726.4370.5
Cash & Short-Term Investments
1,4801,0761,032989.3711.3
Cash Growth
37.57%4.31%4.28%39.08%-11.20%
Accounts Receivable
686.8479.1439.3350185.5
Inventory
6957.438.335.130.5
Other Current Assets
219.2179.497.879.145.5
Total Current Assets
2,5231,7251,6071,454972.8
Net Property, Plant & Equipment
545.2592347.3145.6155.8
Other Intangible Assets
--35.537.2-
Long-Term Investments
1,184864.3849.4401.5624.4
Other Long-Term Assets
379.8537.7412.2330.9319.5
Total Assets
4,6323,7193,2512,3692,073
Accounts Payable
674.3461.6448.8347.6225.8
Current Portion of Long-Term Debt
--170.1169.4-
Other Current Liabilities
69.146.135.920.720
Total Current Liabilities
743.4507.7654.8537.7245.8
Long-Term Debt
----335.1
Long-Term Leases
415.3455.1258.393.5105.3
Other Long-Term Liabilities
219.7166.2106.329.712.3
Total Long-Term Liabilities
635621.3364.6123.2452.7
Total Liabilities
1,3781,1291,019660.9698.5
Common Stock
0.10.10.10.10.1
Additional Paid-in Capital
2,7922,5552,3822,1222,011
Accumulated Other Comprehensive Income
13.15.87-7.9-1.7
Retained Earnings
447.729.2-157.1-406.8-635.8
Shareholders' Equity
3,2532,5902,2321,7081,374
Total Liabilities & Equity
4,6323,7193,2512,3692,073
Total Debt
415.3455.1428.4262.9440.4
Net Cash (Debt)
1,065621603.2726.4270.9
Net Cash Growth
71.51%2.95%-16.96%168.14%-30.31%
Net Cash Per Share
10.395.995.977.342.77
Book Value
3,2532,5902,2321,7081,374
Book Value Per Share
31.7424.9722.1017.2714.03
Tangible Book Value
3,2532,5902,1971,6711,374
Tangible Book Value Per Share
31.7424.9721.7516.8914.03
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.